Comparison and calibration of the 2025 and 2015 American Thyroid Association recurrence-risk classifications in differentiated thyroid cancer
Journal of the Endocrine Society · 02.11.2026 · 10 (12)
DOI: 10.1210/jendso/bvag239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 15.10.2026. Verfasst von Ali S Alzahrani und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Context
The 2025 American Thyroid Association (ATA) guidelines maintained the low- and high-risk categories and subdivided the intermediate-risk category of differentiated thyroid cancer (DTC) into low-intermediate and intermediate-high tiers.
Objective
To determine whether observed rates of structural disease match the risks the 2025 and 2015 ATA classifications assign, and to compare the two systems. Patients and Methods All 258 consecutive adults with DTC diagnosed in 2017 were classified under both systems using initial postoperative data. The main outcome was structural disease at any assessment, compared against the guideline-assigned ranges.
Results
Sixty-three patients (24.4%) were reclassified, including 52 of 121 (43.0%) low-risk patients upstaged. Thirty-two (12.4%) developed structural disease. Observed 2025 rates were 0.0% (95% CI, 0.0-5.3), 1.5% (0.3-8.0), 15.5% (9.3-24.7), and 47.4% (32.5-62.7) for low, low-intermediate, intermediate-high, and high risk. The low-intermediate interval fell entirely below its assigned 10% to 15% range (P = .013 vs the 10% lower bound); the other categories of both systems were consistent with theirs. No patient upstaged from the 2015 low-risk category developed structural disease. Structural disease later developed in 7 of 14 patients with a biochemically incomplete first response, 2 of 79 indeterminate, and 0 of 129 excellent responses. Discrimination did not differ between the 2 systems (ΔAUC 0.002; 95% CI, −0.031 to 0.036).
Conclusion
The 2025 low-intermediate category overestimated recurrence risk in this cohort, and upstaging of low-risk patients identified nobody who developed structural disease. Confirmation in larger multicenter cohorts is needed before these tiers guide treatment intensity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
- Research and Innovation Centre, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
- Department of Medicine, College of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
ORCID-Profile: Ali S Alzahrani, Shaza Samargandy
Zitieren
APA
Alzahrani, A. S., Albasri, E., Alkhamis, A., AlHujilan, A. H., Hakami, A., Binzuman, G., Semilan, M., Demyati, M., AlMasoud, N. A., Alqarni, L., Alanazi, R., Altowyan, Y., Samargandy, S., & Mohamed, G. (2026). Comparison and calibration of the 2025 and 2015 American Thyroid Association recurrence-risk classifications in differentiated thyroid cancer. Journal of the Endocrine Society, 10(12). https://doi.org/10.1210/jendso/bvag239
Vancouver
Alzahrani AS, Albasri E, Alkhamis A, AlHujilan AH, Hakami A, Binzuman G, et al. Comparison and calibration of the 2025 and 2015 American Thyroid Association recurrence-risk classifications in differentiated thyroid cancer. Journal of the Endocrine Society. 2026;10(12). doi:10.1210/jendso/bvag239
BibTeX
@article{Alzahrani2026,
author = {Alzahrani, Ali S and Albasri, Eman and Alkhamis, Ahmed and AlHujilan, Atheer H and Hakami, Asim and Binzuman, Ghadah and Semilan, May and Demyati, Montaha and AlMasoud, Norah A and Alqarni, Lamya and Alanazi, Rehab and Altowyan, Yasser and Samargandy, Shaza and Mohamed, Gamal},
title = {Comparison and calibration of the 2025 and 2015 American Thyroid Association recurrence-risk classifications in differentiated thyroid cancer},
journal = {Journal of the Endocrine Society},
year = {2026},
volume = {10},
number = {12},
doi = {10.1210/jendso/bvag239}
}
EUVIMED